APOE and Parkinson disease: The GNPC dataset represents a substantial advancement in neurodegenerative disease research, by providing a real-world clinical proteomic dataset that comprises over 35,000 (11,270 with APOE genotype) individuals across AD, FTD, PDD, PD, ALS and normal aging from across more than 20 clinical sites in the US, UK and Europe28.